Want to see TSE:VM full AI Analyst Report?
VM Stock Chart & Stats
C$0.17
>-C$0.01(-5.56%)
At close: 4:00 PM EST
C$0.17
>-C$0.01(-5.56%)
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.20
Previous CloseN/A
Volume12.11K
Average Volume (3M)168.65K
Market Cap
C$38.48M
Enterprise ValueC$14.81
Total Cash (Recent Filing)C$441.87K
Total Debt (Recent Filing)C$40.00K
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding226,342,350
10 Day Avg. Volume104,026
30 Day Avg. Volume168,649
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early Revenue TractionRevenue growth of 52.6% indicates early commercial traction from a very small base. If sustained, expanding sales could improve operating leverage and support the company’s transition from development activity toward a more scalable pharmaceutical-materials business.
Low Financial LeverageVery low leverage limits interest and refinancing pressure, preserving financial flexibility while the business develops. A modest debt burden may allow management to direct more future resources toward product qualification, processing capabilities, and commercialization rather than debt service.
Meaningful Asset BaseThe reported asset base provides an existing foundation for a small company focused on barite processing and pharmaceutical applications. While assets do not ensure profitability, they may support continued development and commercialization efforts without relying entirely on new borrowing.
Bears Say
Severe UnprofitabilityDeeply negative gross profit and a large net loss show that the current cost structure is far ahead of revenue generation. This limits internal funding capacity and means durable improvement depends on substantially higher sales, better margins, or lower operating costs.
Persistent Cash BurnNegative operating and free cash flow indicate that the business is consuming cash to operate rather than funding itself. Although the burn improved from the prior annual period, continued outflows create ongoing funding needs and can constrain investment in growth initiatives.
Eroding Capital BaseMaterial equity erosion reflects the cumulative impact of ongoing losses on the company’s capital base. A smaller equity cushion reduces resilience, may increase dependence on future financing, and leaves less capacity to absorb setbacks during commercialization.
Voyageur Pharmaceuticals News
VM FAQ
What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was C$0.07 and its highest was C$0.20 in the past 12 months.
What is Voyageur Pharmaceuticals’s market cap?
Voyageur Pharmaceuticals’s market cap is C$38.48M.
When is Voyageur Pharmaceuticals’s upcoming earnings report date?
Voyageur Pharmaceuticals’s upcoming earnings report date is Nov 02, 2026 which is in 44 days.
How were Voyageur Pharmaceuticals’s earnings last quarter?
Voyageur Pharmaceuticals released its earnings results on Jul 24, 2026. The company reported -C$0.006 earnings per share for the quarter.
Is Voyageur Pharmaceuticals overvalued?
According to Wall Street analysts Voyageur Pharmaceuticals’s price is currently Overvalued.
Does Voyageur Pharmaceuticals pay dividends?
Voyageur Pharmaceuticals does not currently pay dividends.
What is Voyageur Pharmaceuticals’s EPS estimate?
Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyageur Pharmaceuticals have?
Voyageur Pharmaceuticals has 226,342,350 shares outstanding.
What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
Voyageur Pharmaceuticals reported an EPS of -C$0.006 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:VM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine. It possesses complete ownership of three barium sulfate deposits in British Columbia, Canada, two of which are of a quality appropriate for the pharmaceutical barite sector. Furthermore, Voyageur holds stakes in a valuable brine project in Utah, United States, known for its high concentrations of iodine, lithium, and bromine. The company transitioned from its previous name, Voyageur Minerals Ltd., to Voyageur Pharmaceuticals Ltd. in December 2019. Its corporate headquarters are located in Calgary, Canada.